港股上市公司君实生物（01877）今日盘中大涨5.16%，引起市场广泛关注。截至发稿，该股报价14.42港元，成交额1357.1万港元。
消息面上，君实生物近日公告称，公司的特瑞普利单抗（新加坡商品名：LOQTORZI）获得新加坡卫生科学局（HSA）批准上市。该药物联合顺铂和吉西他滨用于复发、不能手术或放疗的，或转移性鼻咽癌成人患者的一线治疗。值得注意的是，特瑞普利单抗成为新加坡首个且唯一获批用于鼻咽癌的肿瘤免疫治疗药物，这一重大突破或成为推动君实生物股价上涨的主要原因。
此外，市场还关注到，近日成立的上海生物医药并购私募基金合伙企业，出资额高达46.6亿元，其股东之一便是君实生物。该基金的经营范围包括股权投资、投资管理、资产管理等活动。这一消息也可能对君实生物的股价产生积极影响，反映了公司在生物医药领域的战略布局和发展潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.